GBT completes its qTerm Vitals device with improvements in temperature measurement algorithms

GBT Technologies Inc.

SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) — GBT Technologies Inc. (OTC PINK: GTCH) (“GBT” or the “Company”) is terminating its qTerm vitals device with improved temperature measurement algorithms, in the goal of continuing to improve its accuracy and feedback. Code enhancements have been made at the high level of the system to advance finger, device, and ambient temperature interactions and reporting. Tests were carried out to finalize the qTerm GEN III prototype device and based on the collected data, GBT finalized the functionalities and characteristics of the device. qTerm, a smart device for human vital signs is intended to measure human vital signs at the touch of a finger. The device includes oxygen (SPO2), heart rate and IR (infrared) type sensors for body temperature, including a coprocessor microchip that provides an advanced calibration algorithm to help users use qTerm. The device comes with a smartphone app and a synced web widget to keep history and provide health analytics. The widget allows the user to view qTerm results worldwide, making it an effective remote telemedicine technology. The device is expected to use GBT’s artificial intelligence technology for recording, analysis and continuous monitoring of vital data. In case of abnormalities, the system will alert, advising further health-related steps. The system will offer API (Application Programming Interface) capabilities to be connected to the healthcare system of hospitals and clinics, allowing healthcare professionals to view patient history and analyses. The GEN III prototype has undergone case, circuit and software modifications to achieve stable and accurate results, targeting personal and clinical use.

“After the completion of the robust code changes, we conclude our qTerm human vitals device. qTerm GEN III has undergone changes to the case structure, electronics and software and we believe it is now ready for commercialization. The most recent code enhancements were aimed at further improving the human/device temperature ratio and measurements interactions. Due to the temperature sensitivity of human extremities, it is difficult to measure body temperature by taking both ambient and external conditions are taken into account. For example, if a user measures their body temperature immediately after having a cold or a hot environment, it may lead to an inaccurate result due to the temperature of the affected fingertip. In this case , the device will warn to wait in normal room temperature for temperature stabilization before re-measuring vital signs. The device will be accompanied by a mobile for iOS and Android platforms, connected via Bluetooth. A synchronized web widget will be available on the qTerm website for users to view anywhere in the world. The widget also provides health-related historical information, analytics, and graphs, making qTerm an effective technology for global telemedicine. Our artificial intelligence technology is the brains of the system and will be trained with the user’s vital data. It will process data, keep history, perform analytics and provide continuous and personal health monitoring. The system will have API capabilities to easily connect to hospital and clinic healthcare information systems. We are now reviewing the commercialization of qTerm and evaluating production possibilities. The fact that qTerm’s readings can be viewed around the world, we believe makes it a robust telemedicine technology to keep our lives safer and healthier,” said Danny Rittman, the company’s CTO.

There is no guarantee that the Company will succeed in researching, developing or implementing this system. In order to successfully implement this concept, the Company will need to raise sufficient capital to support its research and, if research, development and regulatory approval are successful, the Company will need to establish a strategic relationship with a third party that has experience in manufacturing, selling and distributing this product. There is no guarantee that the Company will successfully complete any or all of these critical milestones.

About Us

GBT Technologies, Inc. (OTC ROSE: GTCH) (“GBT”) ( is a development-stage company that considers itself a native of the Internet of Things (IoT), Artificial Intelligence (AI), and mobile-enabled technology platforms used to increase the performance of integrated circuits. GBT has assembled a team with extensive technological expertise and built an intellectual property portfolio consisting of numerous patents. GBT’s mission is to license technology and intellectual property to synergistic partners in hardware and software. Once commercialized, GBT’s goal is to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, core management protocols of data, with tracking software and cloud support (without the need for GPS). GBT envisions this system as the creation of a global mesh network using advanced nodes and super-efficient next-generation IC technology. The heart of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a private, secure and low cost mesh network between all enabled devices. Thus, providing advanced shared processing, management and sharing of the mobile database while using these enhanced mobile features as an alternative to traditional carrier services.

Forward-looking statements

Certain statements contained in this press release may constitute “forward-looking statements”. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that is not directly related to historical or current fact. Actual results may differ materially from those indicated by these forward-looking statements due to various important factors as disclosed in our filings with the Securities and Exchange Commission located on their website ( In addition to these factors, actual future performance, results and results may differ materially due to broader factors, including (without limitation) general industry and market conditions and growth rates. , economic conditions, changes in government and public policy, the Company’s ability to raise capital on acceptable terms, if any, the Company’s successful development of its products and integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and those views are subject to change. However, while the Company may choose to update these forward-looking statements at some point in the future, the Company expressly disclaims any obligation to do so. These forward-looking statements should not be taken to represent the views of the Company as of any date subsequent to the date of the press release.


Dr. Danny Rittman, CTO

[email protected]

Sharon D. Cole